Aethlon Medical, Inc. · NASDAQ:AEMD
Aethlon Medical — Conference Presentation (March 2021)
18 slides from Aethlon Medical's conference presentation, March 2021
Slide 1: March 2021 Presentation for Financial Conferences
NASDAQ: AEMD March 2021 Presentation for Financial Conferences 1
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This investor presentation contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including, without limitation: the ability to enroll patients in the Early Feasibility Studies; the ability to successfully compl
Slide 3: The Aethlon Hemopurifier
** The Aethlon Hemopurifier® ▪ Two FDA “Breakthrough Device” designations • Safety in over 150 patient treatments in human trials or emergency use • Proprietary mechanism of action • Clears life-threatening glycosylated viruses • Designed to clear cancer promoting exosomes 3
Slide 4: Aethlon Medical
Aethlon Medical ▪ Hemopurifier® in human trials for oncology and viral diseases ▪ Experienced management team ▪ Strong cash position ▪ Non-dilutive NCI funding for multiple programs ▪ Based in San Diego 4
Slide 5: Hemopurifier Design
Hemopurifier® Design ▪ Hollow-fiber plasma separator filled with proprietary affinity resin in the extra-capillary space outside of cartridge fibers ▪ Captures enveloped viral pathogens and exosomes in circulating blood based on size and glycosylation ▪ Used with either dialysis or CRRT machine. Pro
Slide 6: Pipeline
Pipeline Early Feasibility Indication Pre-Clinical Study Pivotal Study Approved Oncology Head & Neck Protocol - HP Before Keytruda Other Solid TBD Tumors Viral Infection COVID-19 Emergency use and Protocol HCV Emergency use HIV Safety testing Ebola Emergency use and Protocol Other TBD 6
Slide 7: Hemopurifier Programs
Hemopurifier® Programs Oncology ▪Clearance of cancer promoting exosomes ▪ Potentially synergistic with chemotherapy, immunotherapy, targeted agents ▪ Multiple potential clinical targets: • Breast, head and neck, gastrointestinal, melanoma, other solid tumors ▪ Well characterized markets, development
Slide 8: Why Exosomes?
Why Exosomes? ▪ Key mediators in cell communication and potent drivers in healing and repair ▪ They shed from both normal and malignant cells ▪ Primary means of intra-cellular communication ▪ Tumor derived exosomes (TEX)—released by tumor cells that promote: • Metastasis, chemotherapy/targeted thera
Slide 9: Tumor-derived Exosomes (TEX) Being Released by Tumor cell
Tumor-derived Exosomes (TEX) Being Released by Tumor cell Tumor-derived exosomes Cell membrane Cytoplasm 9
Slide 10: National Cancer Institute Studies
National Cancer Institute Studies ▪ Phase I contract from NCI — Completed “Device Strategy for Differential Isolation of Oncosomes and Non-Malignant Exosomes” ▪ NCI SBIR Grant — Completed “The Hemopurifier® Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation” ▪ Phase II
Slide 11: EFS in Head and Neck Cancer
EFS in Head and Neck Cancer ▪ NCT #04453046 ▪ University of Pittsburgh Hillman Cancer Center ▪ 10-12 subjects with advanced or metastatic HNSSC ▪ Combination with pembrolizumab (Keytruda®) ▪ Keytruda approved June 2019 in front line setting ▪ 4-hour Hemopurifier treatment immediately prior to Keytru
Slide 12: Hemopurifier Treatment of Viral Infections
Hemopurifier® Treatment of Viral Infections ▪ Demonstrated clearance of multiple different viruses in vitro • HIV, dengue, West Nile, influenza, Ebola, herpes, MERS ▪ Safety and viral clearance in four human clinical trials in HCV ▪ Over 120 successful applications in humans with HCV with no safety
Slide 13: Hemopurifier Treatment of SARS-CoV-2/COVID-19
Hemopurifier® Treatment of SARS-CoV-2/COVID-19 ▪ Circulating virus correlates with cytokine levels and poor outcome ▪ Hemopurifier has been shown to clear MERS, another coronavirus ▪ Clears SARS-CoV-2/COVID-19 glycoproteins based on in vitro experiments ▪ IDE supplement for COVID-19 approved June 17
Slide 14: Aethlon Medical Senior Management Team
Aethlon Medical Senior Management Team Charles J. Fisher, Jr., M.D., FACP, FCCP, FCCM, Chief Executive Officer ▪ Academic & Industry thought leader in sepsis & inflammation ▪ Head of critical care—Cleveland Clinic ▪ 35 years industry development experience ▪ Senior executive—Lilly, Abbott, Cardiome
Slide 15: Strong Cash Position
Strong Cash Position ▪ December 31, 2020 Company’s cash balance was approximately $12.1 million ▪ No debt ▪ NASDAQ: AEMD ~12.1 million shares outstanding 1 5
Slide 16: Upcoming News Aethlon Hemopurifier
Upcoming News Aethlon Hemopurifier® 2020-2021 ▪ IDE supplement approved for SARS-CoV-2/COVID-19 ✔ ▪ Emergency treatment of SARS-CoV-2/COVID-19 patients ✔ ▪ EFS initiated for head and neck cancer and first patient treated ✔ ▪ Expected News: ▪ Initiation of SARS-CoV-2 trial ▪ Early clinical data from
Slide 17: Summary
Summary ▪ Unique Hemopurifier® blood purification device ▪ Two FDA Breakthrough Therapy Designations ▪ Multiple therapeutic targets in cancer and viral disease ▪ Management team with well over 100 years healthcare experience 1 7
Slide 18: 9635 Granite Ridge Drive, Suite 100 San Diego, California 92123 Nasdaq: AEMD
9635 Granite Ridge Drive, Suite 100 San Diego, California 92123 858.459.7800 Nasdaq: AEMD www.AethlonMedical.com This presentation may contain predictions, estimates, and other forward looking statements that involve risks and uncertainties, including whether and when our products are successfully d
Aethlon Medical — Conference Presentation (March 2021) on 6ix